Case studies
Real Challenges Turned into Practical Solutions
Modern development programs often span multiple regions, Health Authorities, stakeholders, and regulatory frameworks. Navigating this complexity requires more than technical regulatory expertise. It requires strategic thinking, coordination, and the ability to transform challenges into actionable plans.
The following examples highlight selected projects and situations where A-REG supported clients in development, registration, lifecycle management, Health Authority engagement, reliance pathways, and global regulatory strategy. While every project is different, our objective remains the same: helping clients move forward with clarity, confidence, and purpose, with the ultimate goal of making the product available for patients.
EMA Scientific Advice
Challenge
- Client planned to initiate a Phase 3 Study for an innovative, rare disease medicinal product, with a borderline biotech advanced medicinal therapy (ATMP) designation and a high tech drug device combination.
- Multiple options were considered for the clinical trial in order to support global registrations.
Solution
- A-REG developed the Scientific Advice strategy, authored the briefing package, leveraging the company’s available data and desired areas of clarification and coordinated the EMA interaction.
- Regulatory opportunities relating to product classification, orphan incentives, and pediatric requirements were evaluated and incorporated into the broader development framework.
Benefits
- Regulatory expectations clarified prior to Phase 3, which increased confidence in the proposed registration pathway once Phase 3 data will be available.
- Development strategy aligned with key global markets with reduced risk of future development rework.
- Time and resource efficiency.
Key Words:
R&D, clinical development, scientific advice, Health Authority meetings, initial MA registration, innovative biotech product, drug device combination, ATMP, orphan.
NEW MANUFACTURING SITE & PRESENTATION
Challenge
- Client planned to add a new alternative finished product (DP) manufacturer, that manufactures the product packed in a different container closure system, essentially a new product presentation format = e.g. addition of pre-filled syringe drug product presentation.
- Commercial DP deliveries were planned from the new manufacturer as soon as possible.
- Geographical scope: EMA region as well all countries, that were following the EMA reliance route in their assessment.
Solution
- Developed a global regulatory strategy supporting the introduction of a new manufacturing site and product presentation with EU (EMA) Type II variation, UK (MHRA) line extension as hybrid IRP procedure parallel to EMA assessment, WHO type A variation, Singapore (HSA) MiiV2 (major) variation, including complete current dossier baselining, and Taiwan (TFDA) major variation with PMF process management (GMP certification).
- Supported preparation, authoring and/or review of key CMC and regulatory documentation required for implementation (CTD Module 3, QOS, complete Module 1, etc.).
- Coordinated submissions, reliance activities, and Health Authority interactions across multiple regions.
Benefits
- Time and resource efficiency on client’s and manufacturing site’s side.
- Maximal utilisation of regulatory reliance route, using EMA as a reference: As a result of a reliance procedure approach, minimum CMC documents differed in the data package for each of the HAs, this provided flexibility in manufacturing and batch release of commercial goods as batches could be processed in identical ways for all markets up until the packaging step.
- At the same time optimisation of time-to-market by negotiating with HAs the assessment in parallel to EMA.
Key Words:
Commercial deliveries, additional manufacturing site, new presentation, post-approval life cycle management, major variation, type II variation, line extension, innovative biotech product.
ACCELERATED EUROPEAN REGISTRATION STRATEGY
Challenge
- Client had a biotech product for an unmet medical need in Phase 3 development and was considering the best approach for initial Registration in Europe.
- The aim was to submit Marketing Authorisations Applications (MAA) the quickest possible way in EU, UK and Switzerland.
- Based on regulatory strategy, client was planning to optimise late steps of the Phase 3 data generation to support the most optimal MAA filing.
Solution
- Pre-submission briefing package was authored, and a pre-submission meeting organised with EMA to inform them about the program R&D and clinical status, target product profile, and estimated timelines. Option of conditional marketing authorisation was discussed as an option with conditions and flexibilities outlined.
- Based on the discussion with EMA, an international reliance procedure (IRP) was suggested for UK and a pre-submission meeting with MHRA was organised. Flexibilities as well as potential submission in parallel to EMA´s ongoing assessment was discussed.
- In parallel, a similar approach was suggested to Swissmedic for Switzerland, leveraging EMA as the reference and supported by a local regulatory partner.
Benefits
- Conditional Marketing Authorisation option allowed for parallel submission of the MAA during the completion of the Phase 3 clinical trial, enabling initiation of the assessment while additional data were still being generated.
- Reliance route for UK and Switzerland offered time savings during the regulatory assessment timeline for both countries as well as regulatory dossier content alignment, supporting flexibility for future commercial deliveries.
- Time and resource efficiency.
Key Words:
Unmet clinical need, initial MA registration, conditional marketing authorisation, reliance route, IRP, regulatory strategy, clinical phase 3 development, Health Authority meetings, innovative biotech product.
HEALTH AUTHORITY INTERACTIONS
Challenge
- Client has been planning to file parallel applications in different regions for initial Marketing Authorisation (MA), including WHO pre-qualification, for a biotech product addressing an unmet medical need.
- The Health Authorities (HA) were requesting regular updates and progress reports on the data generation status, filing timelines and further submissions.
- There was a frequent exchange of information among the HAs and ongoing parallel communication was critical for all involved HAs.
Solution
- Preparation of a comprehensive data package detailing current status, extent of data available and timing of future inputs.
- Offered several HAs a joint meeting where information would be shared to support global alignment and eventual joint assessment.
- Organised a shared EMA, TGA and WHO virtual meeting with the client (including several prep and rehearsal meetings, debrief meeting, meeting minutes and follow ups).
Benefits
- Reduced resource requirements through coordinated multi-authority interactions.
- Improved alignment and transparency across participating Health Authorities.
- Facilitated consistent communication regarding development status, timelines, and future submissions.
- Supported efficient planning of global registration activities and regulatory assessments.
Key Words:
Unmet clinical need, Health Authority meetings, initial MA registration, innovative biotech product, biologics.
WHO PREQUALIFICATION
& GLOBAL RELIANCE
STRATEGY
Challenge
- A vaccine manufacturer planned expansion into procurement-driven and emerging markets, where WHO Prequalification (WHO PQ) was a prerequisite for access.
- The company needed to align WHO requirements with existing and planned regulatory submissions while avoiding duplication of effort across multiple target countries.
Solution
- A-REG developed an integrated regulatory strategy combining WHO PQ activities with reference authority submissions and country-specific registration requirements.
- A global reliance roadmap was established, identifying opportunities for authorities to leverage WHO and reference agency assessments.
- Regulatory activities and submission sequencing were coordinated across regions to maximize efficiency.
Benefits
- Reduced duplication of regulatory documentation and assessment activities.
- Accelerated access to multiple WHO-reliant markets.
- Established a globally aligned dossier strategy supporting long-term lifecycle management.
Key Words:
WHO, Prequalifiction, PQ, reliance, emerging markets, vaccines, global registration strategy, market access.
REGULATORY STRATEGY FOR PLATFORM TECHNOLOGY
Challenge
- A biotechnology company was developing multiple medicinal product candidates using a common technology platform.
- The client needed a regulatory approach that would enable future products to leverage existing development knowledge, manufacturing experience, and clinical data while maintaining regulatory credibility and acceptance across multiple jurisdictions.
Solution
- A-REG designed a platform-based regulatory strategy identifying reusable data packages, platform framework, critical platform elements, and product-specific variables, platform-specific evidence requirements and opportunities for cross-program regulatory efficiencies.
- Regulatory expectations across key global jurisdictions were assessed and incorporated into a long-term development framework.
- A strategy for global Health Authority interactions was developed to support validation of the platform approach and inform future development decisions.
Benefits
- Reduced duplication of future development and regulatory activities.
- Identification of platform core aspects helped to focus development activities and prioritize data generation.
- Established a consistent regulatory positioning across multiple programs, with a road map on Health Authority interactions during the development programs to inform decisions.
- Supported accelerated development of follow-on products using the same platform technology, including data leverage from prior knowledge.
- Core platform aspects helped to inform standardized CMC CTD documentation across multiple development programs.
Key Words:
Platform technology, prior data knowledge, biotechnology, biologics, master file, global development, regulatory strategy, data leverage.
EARLY DEVELOPMENT
BIOTECH / UNIVERSITY
SPIN-OFF
Challenge
- A university spin-off company developing a promising biologic candidate had limited regulatory experience and required a development roadmap capable of supporting future clinical development, global registration ambitions, and discussions with potential investors and strategic partners.
Solution
- A-REG performed a comprehensive assessment of development options, including target product profile assessment, indication prioritisation and portfolio opportunities assessment, regulatory pathway evaluation, scientific advice opportunities and eligibility for orphan and pediatric incentives.
- A phased development strategy and regulatory roadmap were established to support efficient development and future interactions with Health Authorities.
Benefits
- Identification of critical development milestones, key decision points, and future Health Authority interactions within a structured roadmap incorporating risks, mitigation measures, and alternative scenarios.
- Reduced uncertainty regarding future regulatory requirements.
- Improved communication of development plans to potential investors and partners.
Key Words:
Biotech, start-up, university spin-off, early development, biologics, orphan designation, clinical development strategy, regulatory strategy, scientific advice.
STRATEGIC REGULATORY DUE DILIGENCE
Challenge
- An investor evaluating a biotechnology asset required an independent assessment of the regulatory strategy, development assumptions, and readiness of the program to support future development, registration, and commercialization activities.
- While significant development activities had already been completed, there was a need to assess whether key regulatory decisions had been validated, critical milestones had been achieved, and the program remained aligned with future registration objectives across target markets.
Solution
- A-REG performed a strategic regulatory due diligence review focused on development and registration readiness (rather than scientific data review).
- The assessment evaluated regulatory pathways, Health Authority interactions, key development milestones, regulatory risks, and alignment of the program with future registration objectives.
- Additional reviews were performed to assess operational and commercialization readiness, including pharmacovigilance structures, quality systems, manufacturing and supply chain considerations, batch release strategy, and other critical elements required to support future market entry.
Benefits
- Independent assessment of regulatory strategy and long-term registration feasibility.
- Early identification of regulatory, operational, and commercial readiness gaps.
- Confirmation of critical milestones achieved and identification of areas requiring further Health Authority engagement.
- Improved understanding of future regulatory requirements, key decision points, and development priorities.
- Increased confidence for investment, acquisition, or strategic partnership discussions.
Key Words:
Strategic regulatory due diligence, development readiness, commercialization readiness, registration, Health Authority interactions, investment support, biotechnology, regulatory risk assessment, licensing, acquisition, alliance.
GLOBAL BATCH RELEASE & TESTING NETWORK
ALIGNMENT
Challenge
- A vaccine manufacturer operated a complex network of manufacturing, testing, and batch release sites supporting multiple international markets.
- Different regional requirements for batch release, certificate acceptance, testing strategies, and local regulatory expectations created operational complexity and limited supply flexibility.
- The organisation needed a practical approach that would support global supply while avoiding unnecessary duplication of testing and release activities.
Solution
- A-REG performed a detailed assessment of batch release, testing, and regulatory requirements across target markets, including areas of overlap, regional specificities, and opportunities for alignment.
- Existing manufacturing, quality control, and release arrangements were evaluated to identify opportunities for simplification, optimisation, and future scalability.
- A practical framework was developed to support efficient use of testing data, integration of additional manufacturing or testing sites, and alignment of global supply activities while maintaining compliance with local regulatory requirements.
Benefits
- Reduced complexity and duplication across manufacturing, testing, and commercial release activities.
- Improved supply chain flexibility and ability to support multiple markets from a coordinated network.
- Established a scalable framework for future expansion of manufacturing, testing, and release capabilities.
- Increased confidence that regulatory, quality, and operational requirements remained aligned with global supply objectives.
Key Words:
Batch release, quality control testing, vaccines, biologics, manufacturing network, CMC strategy, supply chain strategy, regulatory compliance.